Press Release

HealthEquity – $90 Million Follow-On

November 4, 2016

San Diego – November 4, 2016 – Cooley advised the underwriters on HealthEquity’s $89.6 million follow-on offering. The underwriters have a 30-day option to purchase up to 375,000 additional shares of common stock from the selling stockholders.

HealthEquity, which trades on The NASDAQ Global Select Market under the symbol "HQY," is a leader and an innovator in the high growth category of technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions.

Jefferies and Raymond James acted as joint book-running managers for the offering.

Cooley advised the underwriters on HealthEquity’s 2014 IPO and subsequent follow-on offerings in May 2015 and September 2015.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.